

Special Issue

Proteomic and Genomic Profiling of Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer is one of the deadliest forms of cancer, with a 5-year survival rate of 10%. The most common treatment for pancreatic cancer is surgery and chemotherapy; however, to date, both strategies have had limited success. To combat pancreatic cancer, in recent years, a significant amount of attention has been paid to immunotherapy and personalized medicine. PD1 therapy and presently available CART therapies are failing to treat pancreatic cancer, and there is a pressing need to collect more clinical biomarkers for the development of new therapeutic targets for personalized medicine. In the age of high-throughput techniques, genomics and proteomics in particular have had a significant impact on identifying mutations in oncogenes such as KRAS and other relevant new biomarkers for chemotherapy and immunotherapy. Using the current understanding of immunotherapy, genomics and proteomics analysis of pancreatic cancer patient samples will lead to the discovery of new targets that will help in the development of novel therapeutics.

Guest Editor

Dr. Aftab Alam

Department of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA

Deadline for manuscript submissions

closed (31 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/168723

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)